Relmada Therapeutics (RLMD) announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada’s Clinical Advisory Board to support the development of NDV-01 for the potential treatment of non-muscle invasive bladder cancer. Relmada intends to initiate the Phase 3 program for NDV-01 in H1 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Relmada Therapeutics Updates Corporate Presentation on NDV-01
- Relmada Therapeutics regains compliance with Nasdaq min bid price requirement
- Relmada Therapeutics Regains Nasdaq Compliance
- Relmada Therapeutics Highlights Strategic Progress to Shareholders
- Relmada Therapeutics CEO remains ‘optimistic’ about company’s future